The ADAURA trial is the first global phase 3 study to show an overall survival benefit with targeted treatment in resected, EGFR-mutated, stage IB-IIIA non-small-cell lung cancer, according to study presenter Roy S. Herbst, MD, PhD.
Curative surgery for non-small cell lung cancer after treatment with nivolumab plus relatlimab is as safe as surgery after nivolumab alone, the NEOpredict-Lung study suggests.
A regulatory decision is expected on November 27, 2023.
Researchers are evaluating zimberelimab in combination with domvanalimab and etrumadenant in patients with previously treated, metastatic NSCLC.
Research presented at AACR 2023 highlighted a potential new standard of care for NSCLC and other novel treatments for NSCLC and ES-SCLC.
Researchers are conducting a phase 2b study to evaluate sutetinib maleate in patients with locally advanced or metastatic NSCLC.
Researchers are conducting a phase 2 study to evaluate sotorasib in combination with cisplatin or carboplatin and pemetrexed for patients with KRAS-mutated, nonsquamous NSCLC.
Decreased mobility and depression may be risk factors for irAEs among older adults with advanced cancer who are receiving ICI therapy.
A multi-pronged intervention can increase biomarker testing in patients with metastatic non-small cell lung cancer, research suggests.
Patients with advanced cancer have better outcomes if they have high TMB prior to treatment with an ICI, new research suggests.
